Cargando…

Neurodegeneration in diabetic retinopathy: does it really matter?

The concept of diabetic retinopathy as a microvascular disease has evolved, in that it is now considered a more complex diabetic complication in which neurodegeneration plays a significant role. In this article we provide a critical overview of the role of microvascular abnormalities and neurodegene...

Descripción completa

Detalles Bibliográficos
Autores principales: Simó, Rafael, Stitt, Alan W., Gardner, Thomas W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6096638/
https://www.ncbi.nlm.nih.gov/pubmed/30030554
http://dx.doi.org/10.1007/s00125-018-4692-1
_version_ 1783348140695355392
author Simó, Rafael
Stitt, Alan W.
Gardner, Thomas W.
author_facet Simó, Rafael
Stitt, Alan W.
Gardner, Thomas W.
author_sort Simó, Rafael
collection PubMed
description The concept of diabetic retinopathy as a microvascular disease has evolved, in that it is now considered a more complex diabetic complication in which neurodegeneration plays a significant role. In this article we provide a critical overview of the role of microvascular abnormalities and neurodegeneration in the pathogenesis of diabetic retinopathy. A special emphasis is placed on the pathophysiology of the neurovascular unit (NVU), including the contributions of microvascular and neural elements. The potential mechanisms linking retinal neurodegeneration and early microvascular impairment, and the effects of neuroprotective drugs are summarised. Additionally, we discuss how the assessment of retinal neurodegeneration could be an important index of cognitive status, thus helping to identify individuals at risk of dementia, which will impact on current procedures for diabetes management. We conclude that glial, neural and microvascular dysfunction are interdependent and essential for the development of diabetic retinopathy. Despite this intricate relationship, retinal neurodegeneration is a critical endpoint and neuroprotection, itself, can be considered a therapeutic target, independently of its potential impact on microvascular disease. In addition, interventional studies targeting pathogenic pathways that impact the NVU are needed. Findings from these studies will be crucial, not only for increasing our understanding of diabetic retinopathy, but also to help to implement a timely and efficient personalised medicine approach for treating this diabetic complication. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00125-018-4692-1) contains a slideset of the figures for download, which is available to authorised users.
format Online
Article
Text
id pubmed-6096638
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-60966382018-08-24 Neurodegeneration in diabetic retinopathy: does it really matter? Simó, Rafael Stitt, Alan W. Gardner, Thomas W. Diabetologia Review The concept of diabetic retinopathy as a microvascular disease has evolved, in that it is now considered a more complex diabetic complication in which neurodegeneration plays a significant role. In this article we provide a critical overview of the role of microvascular abnormalities and neurodegeneration in the pathogenesis of diabetic retinopathy. A special emphasis is placed on the pathophysiology of the neurovascular unit (NVU), including the contributions of microvascular and neural elements. The potential mechanisms linking retinal neurodegeneration and early microvascular impairment, and the effects of neuroprotective drugs are summarised. Additionally, we discuss how the assessment of retinal neurodegeneration could be an important index of cognitive status, thus helping to identify individuals at risk of dementia, which will impact on current procedures for diabetes management. We conclude that glial, neural and microvascular dysfunction are interdependent and essential for the development of diabetic retinopathy. Despite this intricate relationship, retinal neurodegeneration is a critical endpoint and neuroprotection, itself, can be considered a therapeutic target, independently of its potential impact on microvascular disease. In addition, interventional studies targeting pathogenic pathways that impact the NVU are needed. Findings from these studies will be crucial, not only for increasing our understanding of diabetic retinopathy, but also to help to implement a timely and efficient personalised medicine approach for treating this diabetic complication. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00125-018-4692-1) contains a slideset of the figures for download, which is available to authorised users. Springer Berlin Heidelberg 2018-07-20 2018 /pmc/articles/PMC6096638/ /pubmed/30030554 http://dx.doi.org/10.1007/s00125-018-4692-1 Text en © The Author(s) 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Review
Simó, Rafael
Stitt, Alan W.
Gardner, Thomas W.
Neurodegeneration in diabetic retinopathy: does it really matter?
title Neurodegeneration in diabetic retinopathy: does it really matter?
title_full Neurodegeneration in diabetic retinopathy: does it really matter?
title_fullStr Neurodegeneration in diabetic retinopathy: does it really matter?
title_full_unstemmed Neurodegeneration in diabetic retinopathy: does it really matter?
title_short Neurodegeneration in diabetic retinopathy: does it really matter?
title_sort neurodegeneration in diabetic retinopathy: does it really matter?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6096638/
https://www.ncbi.nlm.nih.gov/pubmed/30030554
http://dx.doi.org/10.1007/s00125-018-4692-1
work_keys_str_mv AT simorafael neurodegenerationindiabeticretinopathydoesitreallymatter
AT stittalanw neurodegenerationindiabeticretinopathydoesitreallymatter
AT gardnerthomasw neurodegenerationindiabeticretinopathydoesitreallymatter